ROIV
Roivant Sciences Ltd.·Healthcare
29.58
0.287%(−0.09)
Close PriceLast Updated: — ET
52W L: $10.5952W H: $32.79
ROIV NEWS
seekingalpha.com
6d ago
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
seekingalpha.com
May 20
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
marketbeat.com
May 20
Roivant Sciences Q4 Earnings Call Highlights
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.
zacks.com
May 20
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
globenewswire.com
May 20
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update.
zacks.com
May 19
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
